Lilly bets up to $250 million in AI drug discovery pact with XtalPi
30 May 2023
Eli Lilly has inked a deal worth up to $250 million in upfront and milestone payments for access to Chinese startup XtalPi's integrated artificial intelligence (AI) capabilities and robotics platform to uncover drug candidates directed against an undisclosed target. "With a closed loop of AI and quantum physics algorithms working in sync with the data factory of large-scale robotics experiments, [we are] uniquely equipped to tackle challenging novel targets," remarked XtalPi CEO Jian Ma in a statement Tuesday.
Under the deal, XtalPi will use its technology to deliver a novel drug compound that Eli Lilly will pursue in clinical and commercial development. XtalPi says its ID4Inno small-molecule drug discovery platform uses AI to generate and investigate a "target-specific mega chemical space" in order to rapidly pinpoint the most promising lead series.
Each set of synthesised molecules is tested using the company's internal biochemical, cellular, pharmacodynamic and pharmacokinetic assay capabilities. Project-specific R&D data is then fed into generative AI models until an "optimal" candidate emerges. XtalPi said it has hundreds of autonomous robotic workstations that can conduct "precise and energy-efficient parallel chemical synthesis and assays" around-the-clock.
Over 200 partners
XtalPi raised $400 million in Series D financing in 2021, after securing more than $300 million the year before. The startup said it has worked with over 200 pharmaceutical clients and research institutions around the world, including Pfizer, CK Life Sciences, Signet Therapeutics, and Johnson & Johnson's Janssen.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.